Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Search
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Employees empower small dairy producers
Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
CT-155: Prescription digital therapeutic
CT-155: Prescription digital therapeutic
International recognition for Boehringer Ingelheim BioXcellence™
International recognition for Boehringer Ingelheim BioXcellence™
Day and night: veterinary clinic for pet care
Our primary focus is supporting our vets to care for our animal friends, providing on-time medicines when needed. Learn how we do this in our daily lives.
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Boehringer upgrade in Access to Medicine Health Ranking
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Retinal Health
Human Pharma Clinical Pipeline Retinal Health therapeutic area
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Lung Diseases
Lung Diseases
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.